Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 10/20 | 0.78 |
| ▸ | FOLR1 | P15328 | 7/20 | 0.78 |
| ▸ | SLC46A1 | Q96NT5 | 7/20 | 0.78 |
| ▸ | SLC19A1 | P41440 | 6/20 | 0.78 |
| ▸ | GART | P22102 | 6/20 | 0.78 |
| ▸ | DHFR | P00374 | 4/20 | 0.78 |
| ▸ | FOLR2 | P14207 | 3/20 | 0.78 |
| ▸ | ATIC | P31939 | 2/20 | 0.78 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.78 |
| ▸ | FRK | P42685 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13181213 | 1.00 | TYMS (0.78) | TYMSFOLR1SLC46A1SLC19A1GART | |
| SCHEMBL12314789 | 0.90 | TYMS (0.66) | TYMSFOLR1SLC46A1SLC19A1GART | |
| SCHEMBL12598435 | 0.90 | TYMS (0.66) | TYMSFOLR1SLC46A1SLC19A1GART | |
| SCHEMBL12042271 | 0.90 | TYMS (0.66) | TYMSFOLR1SLC46A1SLC19A1GART | |
| Pemetrexed SCHEMBL7144918 | 0.88 | GART (1.00) | TYMSFOLR1SLC46A1SLC19A1GART | |
| Pemetrexed SCHEMBL5959741 | 0.88 | GART (1.00) | TYMSFOLR1SLC46A1SLC19A1GART | |
| Pemetrexed SCHEMBL209720 | 0.88 | GART (1.00) | TYMSFOLR1SLC46A1SLC19A1GART | |
| SCHEMBL12180576 | 0.88 | TYMS (0.80) | TYMSFOLR1SLC46A1SLC19A1GART | |
| SCHEMBL12238844 | 0.87 | TYMS (0.74) | TYMSFOLR1SLC46A1SLC19A1GART | |
| SCHEMBL12314803 | 0.87 | TYMS (0.60) | TYMSFOLR1SLC46A1SLC19A1GART |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220273607-A1 | METHODS OF USING MODIFIED CYTOTOXINS TO TREAT CANCER | NORTHWESTERN UNIVERSITY (US) | 2022-09-01 | — | — | US | disclosed |
| US-20210047338-A1 | MODIFIED CYTOTOXINS AND THEIR THERAPEUTIC USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-02-18 | — | — | US | disclosed |
| US-10654864-B2 | Modified cytotoxins and their therapeutic use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-05-19 | — | — | US | disclosed |
| US-10286079-B2 | Modified cytotoxins and their therapeutic use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180222915-A1 | MODIFIED CYTOTOXINS AND THEIR THERAPEUTIC USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-08-09 | — | — | US | disclosed |
| US-10023581-B2 | Modified cytotoxins and their therapeutic use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170080094-A1 | MODIFIED CYTOTOXINS AND THEIR THERAPEUTIC USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023581-B2 | Modified cytotoxins and their therapeutic use | ANXA5, TP53, FABP1 | TYMS 3282/4885FOLR1 2137/4885SLC46A1 3286/4885 |
| US-10286079-B2 | Modified cytotoxins and their therapeutic use | ANXA5, TP53, FABP1 | TYMS 3282/4885FOLR1 2137/4885SLC46A1 3286/4885 |
| US-20180222915-A1 | MODIFIED CYTOTOXINS AND THEIR THERAPEUTIC USE | ANXA5, TP53, FABP1 | TYMS 3282/4885FOLR1 2137/4885SLC46A1 3286/4885 |
| US-20220273607-A1 | METHODS OF USING MODIFIED CYTOTOXINS TO TREAT CANCER | SLC47A2, SLC27A2, SLC27A1 | TYMS 1735/4885FOLR1 165/4885SLC46A1 34/4885 |
| US-20210047338-A1 | MODIFIED CYTOTOXINS AND THEIR THERAPEUTIC USE | ANXA5, TP53, FABP1 | TYMS 3282/4885FOLR1 2137/4885SLC46A1 3286/4885 |
| US-20170080094-A1 | MODIFIED CYTOTOXINS AND THEIR THERAPEUTIC USE | ANXA5, TP53, FABP1 | TYMS 3282/4885FOLR1 2137/4885SLC46A1 3286/4885 |
| US-10654864-B2 | Modified cytotoxins and their therapeutic use | ANXA5, TP53, FABP1 | TYMS 3282/4885FOLR1 2137/4885SLC46A1 3286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.